A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Gerd R BurmesterIain B McInnesJoel KremerPedro MirandaMariusz KorkoszJiri VencovskyAndrea Rubbert-RothEduardo MyslerMatthew A SleemanAlex GodwoodDominic SinibaldiXiang GuoWendy I WhiteBing WangChi-Yuan WuPatricia C RyanDavid CloseMichael E Weinblattnull null

Published in: Annals of the rheumatic diseases (2017)

NCT01706926; results.

Keyphrases

monoclonal antibody
rheumatoid arthritis
clinical trial
open label
study protocol
randomized controlled trial
disease activity
double blind
systemic lupus erythematosus
interstitial lung disease
ankylosing spondylitis
systemic sclerosis
cerebrospinal fluid